Trial Profile
Palifermin Treatment of Toxic Epidermal Necrolysis
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 02 Dec 2016
Price :
$35
*
At a glance
- Drugs Palifermin (Primary)
- Indications Stevens-Johnson syndrome; Toxic epidermal necrolysis
- Focus Therapeutic Use
- Sponsors Swedish Orphan Biovitrum
- 09 Aug 2016 Status changed from recruiting to discontinued as low enrollment numbers precluded completion of the study during a reasonable amount of time.
- 17 Feb 2014 New trial record